Julia Forbess
Partner
Corporate
Julia
Forbess
Julia
Forbess
Partner
Corporate
Julia represents public technology and biotech companies in a variety of transactional matters with an emphasis on initial public offerings and follow-on offerings in equity and convertible debt, including 144A offerings. Representative issuer-side IPOs include Arcutis Biotherapeutics, Loxo Oncology, Morphic Holding, Stoke Therapeutics and Workday. She also represents public companies in SEC regulatory compliance and corporate governance matters.
While attending law school, Julia was a member of the Chicago Journal of International Law and received the Joseph Henry Beale Prize for legal writing.
- Arcutis in its $183.3M initial public offering
- Audentes in its $231.4M follow-on offering
- Day One Biopharmaceuticals in its $184M initial public offering
- Dexcom in its $1.05B convertible senior notes offering and in its $850M convertible senior notes offering
- Elevation Oncology in its $100M initial public offering
- Graybug Vision in its merger agreement with CalciMedica, its $90M initial public offering and its $80M Series C financing
- Kalvista in its reverse merger with Carbylan, as well as in its $78.2M follow-on offering
- Loxo Oncology in its $8B acquisition by Lilly, as well as in its $260.8M follow-on offering and in its initial public offering
- Graybug Vision in its merger agreement with CalciMedica, its $90M initial public offering and its $80M Series C financing
- Kalvista in its reverse merger with Carbylan, as well as in its $78.2M follow-on offering
- Loxo Oncology in its $8B acquisition by Lilly, as well as in its $260.8M follow-on offering and in its initial public offering
- Morphic Therapeutic in its $103.5M initial public offering and its $245M follow-on offering
- Neoleukin in its $86.2M follow-on offering
- Prelude Therapeutics in its initial public offering and in its $172.5M follow-on offering
- Stoke Therapeutics in its $163M initial public offering
- Glu Mobile in its $2.4B acquisition by Electronic Arts
- Redfin in its $258.3M concurrent public offerings of stock and convertible notes
- VELO3D in its combination agreement with JAWS Spitfire SPAC
- Workday in its $732.5M initial public offering
- Underwriters in Zillow Group’s $747.5M concurrent public offerings of stock and convertible notes
- Arcutis in its $183.3M initial public offering
- Audentes in its $231.4M follow-on offering
- Day One Biopharmaceuticals in its $184M initial public offering
- Dexcom in its $1.05B convertible senior notes offering and in its $850M convertible senior notes offering
- Elevation Oncology in its $100M initial public offering
- Graybug Vision in its merger agreement with CalciMedica, its $90M initial public offering and its $80M Series C financing
- Kalvista in its reverse merger with Carbylan, as well as in its $78.2M follow-on offering
- Loxo Oncology in its $8B acquisition by Lilly, as well as in its $260.8M follow-on offering and in its initial public offering
- Graybug Vision in its merger agreement with CalciMedica, its $90M initial public offering and its $80M Series C financing
- Kalvista in its reverse merger with Carbylan, as well as in its $78.2M follow-on offering
- Loxo Oncology in its $8B acquisition by Lilly, as well as in its $260.8M follow-on offering and in its initial public offering
- Morphic Therapeutic in its $103.5M initial public offering and its $245M follow-on offering
- Neoleukin in its $86.2M follow-on offering
- Prelude Therapeutics in its initial public offering and in its $172.5M follow-on offering
- Stoke Therapeutics in its $163M initial public offering
- Glu Mobile in its $2.4B acquisition by Electronic Arts
- Redfin in its $258.3M concurrent public offerings of stock and convertible notes
- VELO3D in its combination agreement with JAWS Spitfire SPAC
- Workday in its $732.5M initial public offering
- Underwriters in Zillow Group’s $747.5M concurrent public offerings of stock and convertible notes
- Cisco Systems
- Day One Biopharmaceuticals
- Dexcom
- KalVista
- Morphic Therapeutic
- Neoleukin Therapeutics
- Prelude Therapeutics
- Workday
- Cisco Systems
- Day One Biopharmaceuticals
- Dexcom
- KalVista
- Morphic Therapeutic
- Neoleukin Therapeutics
- Prelude Therapeutics
- Workday
[Julia] is a real rising star with exceptional customer service."
Chambers USA, Client Quote
2023 Edition
Recognition Recognition Recognition
Recognition Recognition Recognition
Chambers USA
2023-2024
Recognized by Chambers USA as an up and coming lawyer in Capital Markets: Debt & Equity in California and the Western United States
LMG Life Sciences
2023
Named by LMG Life Sciences as a U.S. Rising Star for Financial and Corporate Law
Super Lawyers
2020
Named by Northern California Super Lawyers as a Rising Star for Business/Corporate law
U.S. News - Best Lawyers
2020-2021
Named by The Best Lawyers in America to its Ones to Watch list for Securities / Capital Markets Law (The Ones to Watch awards recognize extraordinary lawyers who have been in private practice for less than 10 years in the United States)
Chambers USA
2023-2024
Recognized by Chambers USA as an up and coming lawyer in Capital Markets: Debt & Equity in California and the Western United States
LMG Life Sciences
2023
Named by LMG Life Sciences as a U.S. Rising Star for Financial and Corporate Law
Super Lawyers
2020
Named by Northern California Super Lawyers as a Rising Star for Business/Corporate law
U.S. News - Best Lawyers
2020-2021
Named by The Best Lawyers in America to its Ones to Watch list for Securities / Capital Markets Law (The Ones to Watch awards recognize extraordinary lawyers who have been in private practice for less than 10 years in the United States)